CXCL12 and neoplasm: The CXCL12/CXCR4 pathway is also implicated in the activation of CD44+/CD133+ prostate progenitor population, a drug-resistant population of cells that lead to tumor relapse and affects differentiation potential, cell adhesion, clonal growth and tumorigenicity of PCa cells [523].